Comparison of BCG Immunotherapy and Adriamycin for Superficial Bladder Cancer
Research committees
Treatment
Publication Information Expand/Collapse
2008
The Southwest Oncology Group: progress in cancer research [PMID18929152]
1996
Local toxicity patterns associated with intravesical bacillus calmette-guerin. A Southwest Oncology Group study.
1991
A randomized clinical trial of intravesical doxorubicin immunotherapy with Bacille Calmette-Guerin for transitional carcinoma of the bladder. A Southwest Oncology Group study.
1990
Effect of colony-forming unit dose of connaught BCG on outcome to immunotherapy in superficial bladder cancer: A Southwest Oncology Group study.
Fatal sepsis following intravesical bacillus calmette-guerin administrations for bladder cancer.
1989
BCG versus adriamycin intravesical therapy for in situ and papillary transitional cell carcinoma of the urinary bladder: A Southwest Oncology Group study
1986
A trial of bacillus calmette-guerin versus adriamycin in superficial bladder cancer: A South-west Oncology Group study.
1985
BCG versus adriamycin in bladder cancer: A Southwest Oncology Group study.
BCG versus adriamycin in the treatment of transitional cell carcinoma in-situ: A Southwest Oncology Group study.
Intravesical adriamycin for recurrent superficial bladder cancer: A Southwest Oncology Group study.
BCG versus adriamycin in bladder cancer: A Southwest Oncology Group study.
1984
Southwest Oncology Group experience with randomized protocols for bladder cancer.